Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Current Assets: 2019-2025

Historic Current Assets for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to $839.4 million.

  • BridgeBio Pharma's Current Assets rose 88.80% to $839.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $839.4 million, marking a year-over-year increase of 88.80%. This contributed to the annual value of $720.7 million for FY2024, which is 50.90% up from last year.
  • Per BridgeBio Pharma's latest filing, its Current Assets stood at $839.4 million for Q3 2025, which was down 7.99% from $912.3 million recorded in Q2 2025.
  • Over the past 5 years, BridgeBio Pharma's Current Assets peaked at $945.1 million during Q1 2021, and registered a low of $432.9 million during Q2 2023.
  • Moreover, its 3-year median value for Current Assets was $616.2 million (2024), whereas its average is $642.1 million.
  • As far as peak fluctuations go, BridgeBio Pharma's Current Assets tumbled by 43.87% in 2023, and later spiked by 88.80% in 2025.
  • BridgeBio Pharma's Current Assets (Quarterly) stood at $888.9 million in 2021, then tumbled by 38.25% to $548.9 million in 2022, then declined by 12.98% to $477.6 million in 2023, then surged by 50.90% to $720.7 million in 2024, then soared by 88.80% to $839.4 million in 2025.
  • Its last three reported values are $839.4 million in Q3 2025, $912.3 million for Q2 2025, and $695.2 million during Q1 2025.